You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
We do not review or control the content on non-Medtronic sites, and we are not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations.
Click “OK” to confirm you are a Healthcare Professional.
Every day, we want to feel life in all its colors and shades. But little by little, Parkinson’s chips away those moments, those minutes and so many of life’s simple pleasures.
You are not alone. Medtronic DBS therapy can help you improve your quality of life and feel more like your old self again.
The biggest thing for me is I have my smile back.
BE MORE YOU, LIKE ANDY
with Parkinson’s who have DBS surgery experience improvements, if candidates are carefully selected and if the lead is correctly placed.2
EXPLORE THE BENEFITSI still feel better now after 10 years of DBS than before my surgery.
BE MORE CONFIDENT, LIKE LAURA
Medtronic supplemental analysis: supplement to EPDA website update re patient barriers and claims-v17-Sept-2015
The 'gold standard' of evaluating the success rate of DBS is based on the overall motor function evaluation using the UPDRS III scale. The scientifically accepted method for evaluation of the MCIC (minimally clinically important change) is at least 5 points in the UPDRS III scale. The evaluation of 'off medication' allows reflection of the impact of DBS, albeit an artificially created 'off' condition. It has not been typically reported in the publications, but we have completed the above additional analyses of the databases available in both the published evidence (only randomised control trials have been considered for this). The above analysis works for Medtronic devices only.
Based on recommendations by European and national medical societies
Analyses based on PD comorbidities recommended for MRI in Europe. The % was calculated for a real-life PD population potentially eligible for DBS, from US commercial health insurance database (Conroy et al, conference presentation, ECR 2015, Vienna).